Literature DB >> 26614104

Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.

An Moonen1, Vito Annese2, Ann Belmans3, Albert J Bredenoord4, Stanislas Bruley des Varannes5, Mario Costantini6, Bertrand Dousset7, J I Elizalde8, Uberto Fumagalli9, Marianne Gaudric10, Antonio Merla11, Andre J Smout4, Jan Tack1, Giovanni Zaninotto12, Olivier R Busch13, Guy E Boeckxstaens1.   

Abstract

OBJECTIVE: Achalasia is a chronic motility disorder of the oesophagus for which laparoscopic Heller myotomy (LHM) and endoscopic pneumodilation (PD) are the most commonly used treatments. However, prospective data comparing their long-term efficacy is lacking.
DESIGN: 201 newly diagnosed patients with achalasia were randomly assigned to PD (n=96) or LHM (n=105). Before randomisation, symptoms were assessed using the Eckardt score, functional test were performed and quality of life was assessed. The primary outcome was therapeutic success (presence of Eckardt score ≤3) at the yearly follow-up assessment. The secondary outcomes included the need for re-treatment, lower oesophageal sphincter pressure, oesophageal emptying and the rate of complications.
RESULTS: In the full analysis set, there was no significant difference in success rate between the two treatments with 84% and 82% success after 5 years for LHM and PD, respectively (p=0.92, log-rank test). Similar results were obtained in the per-protocol analysis (5-year success rates: 82% for LHM vs. 91% for PD, p=0.08, log-rank test). After 5 years, no differences in secondary outcome parameter were observed. Redilation was performed in 24 (25%) of PD patients. Five oesophageal perforations occurred during PD (5%) while 12 mucosal tears (11%) occurred during LHM.
CONCLUSIONS: After at least 5 years of follow-up, PD and LHM have a comparable success rate with no differences in oesophageal function and emptying. However, 25% of PD patients require redilation during follow-up. Based on these data, we conclude that either treatment can be proposed as initial treatment for achalasia. TRIAL REGISTRATION NUMBERS: Netherlands trial register (NTR37) and Current Controlled Trials registry (ISRCTN56304564). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  ACHALASIA

Mesh:

Year:  2015        PMID: 26614104     DOI: 10.1136/gutjnl-2015-310602

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  73 in total

Review 1.  Achalasia: current therapeutic options.

Authors:  Zubin Arora; Prashanthi N Thota; Madhusudhan R Sanaka
Journal:  Ther Adv Chronic Dis       Date:  2017-06-23       Impact factor: 5.091

Review 2.  Advances in Management of Esophageal Motility Disorders.

Authors:  Peter J Kahrilas; Albert J Bredenoord; Dustin A Carlson; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

Review 3.  Expert consensus document: Advances in the management of oesophageal motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes.

Authors:  Peter J Kahrilas; Albert J Bredenoord; Mark Fox; C Prakash Gyawali; Sabine Roman; André J P M Smout; John E Pandolfino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

4.  Esophagogastric Junction Distensibility on Functional Lumen Imaging Probe Topography Predicts Treatment Response in Achalasia-Anatomy Matters!

Authors:  Anand S Jain; Dustin A Carlson; Joseph Triggs; Michael Tye; Wenjun Kou; Ryan Campagna; Eric Hungness; Donald Kim; Peter J Kahrilas; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2019-09       Impact factor: 10.864

Review 5.  Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.

Authors:  Mitchell S Cappell; Stavros Nicholas Stavropoulos; David Friedel
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

6.  POEM: clinical outcomes beyond 5 years.

Authors:  Sarah C McKay; Christy M Dunst; Ahmed M Sharata; Reid Fletcher; Kevin M Reavis; Daniel Davila Bradley; Steven R DeMeester; Dolores Müller; Brett Parker; Lee L Swanström
Journal:  Surg Endosc       Date:  2021-01-04       Impact factor: 4.584

7.  Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders.

Authors:  Ezra N Teitelbaum; Christy M Dunst; Kevin M Reavis; Ahmed M Sharata; Marc A Ward; Steven R DeMeester; Lee L Swanström
Journal:  Surg Endosc       Date:  2017-06-29       Impact factor: 4.584

Review 8.  Peroral endoscopic myotomy (POEM) for treating esophageal motility disorders.

Authors:  Ian Wong; Simon Law
Journal:  Ann Transl Med       Date:  2017-04

9.  Tailoring Therapy for Achalasia.

Authors:  Joel E Richter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-05

10.  S093: pneumatic balloon dilation for palliation of recurrent symptoms of achalasia after esophagomyotomy.

Authors:  Riley D Stewart; Jeffrey Hawel; Daniel French; Drew Bethune; James Ellsmere
Journal:  Surg Endosc       Date:  2018-06-15       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.